121 related articles for article (PubMed ID: 14586558)
1. Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.
Tognon G; Frapolli R; Zaffaroni M; Erba E; Zucchetti M; Faircloth GT; D'Incalci M
Cancer Chemother Pharmacol; 2004 Jan; 53(1):89-90. PubMed ID: 14586558
[No Abstract] [Full Text] [Related]
2. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
Allavena P; Signorelli M; Chieppa M; Erba E; Bianchi G; Marchesi F; Olimpio CO; Bonardi C; Garbi A; Lissoni A; de Braud F; Jimeno J; D'Incalci M
Cancer Res; 2005 Apr; 65(7):2964-71. PubMed ID: 15805300
[TBL] [Abstract][Full Text] [Related]
4. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.
Brandon EF; Meijerman I; Klijn JS; den Arend D; Sparidans RW; Lázaro LL; Beijnen JH; Schellens JH
Anticancer Drugs; 2005 Oct; 16(9):935-43. PubMed ID: 16162970
[TBL] [Abstract][Full Text] [Related]
5. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
6. New drugs from the sea.
D'Incalci M; Simone M; Tavecchio M; Damia G; Garbi A; Erba E
J Chemother; 2004 Nov; 16 Suppl 4():86-9. PubMed ID: 15688619
[TBL] [Abstract][Full Text] [Related]
7. Sea squirt assaults sarcomas.
Burton A
Lancet Oncol; 2002 Nov; 3(11):648. PubMed ID: 12424055
[No Abstract] [Full Text] [Related]
8. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA
Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
[TBL] [Abstract][Full Text] [Related]
9. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
Cuevas C; Francesch A
Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
[TBL] [Abstract][Full Text] [Related]
10. Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas?
Verweij J
J Clin Oncol; 2005 Aug; 23(24):5420-3. PubMed ID: 16109999
[No Abstract] [Full Text] [Related]
11. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
12. [Ecteinascidin 743].
Lansiaux A; Bailly C
Bull Cancer; 1999 Feb; 86(2):139-41. PubMed ID: 10094523
[No Abstract] [Full Text] [Related]
13. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).
Erba E; Bergamaschi D; Bassano L; Ronzoni S; Di Liberti G; Muradore I; Vignati S; Faircloth G; Jimeno J; D'Incalci M
Br J Cancer; 2000 May; 82(10):1732-9. PubMed ID: 10817511
[TBL] [Abstract][Full Text] [Related]
14. Biology of ovarian cancer and trabectedin mechanism of action.
Ray-Coquard I
Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
[TBL] [Abstract][Full Text] [Related]
15. In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.
Simoens C; Korst AE; De Pooter CM; Lambrechts HA; Pattyn GG; Faircloth GT; Lardon F; Vermorken JB
Br J Cancer; 2003 Dec; 89(12):2305-11. PubMed ID: 14676811
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic agents in the era of molecular targets and genomics.
Chabner BA
Oncologist; 2002; 7 Suppl 3():34-41. PubMed ID: 12165653
[TBL] [Abstract][Full Text] [Related]
17. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
18. Ecteinascidin-743.
Held-Warmkessel J
Clin J Oncol Nurs; 2003; 7(3):313-9. PubMed ID: 12793338
[TBL] [Abstract][Full Text] [Related]
19. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
20. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.
Manara MC; Perdichizzi S; Serra M; Pierini R; Benini S; Hattinger CM; Astolfi A; Bagnati R; D'Incalci M; Picci P; Scotlandi K
Int J Oncol; 2005 Dec; 27(6):1605-16. PubMed ID: 16273217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
